Novavax, Inc. (NVV1.F) XETRA

7.31

+0.035(+0.48%)

Updated at September 30 07:56AM

Currency In EUR

Novavax, Inc.

Address

21 Firstfield Road

Gaithersburg, MD 20878

United States of America

Phone

240 268 2000

Sector

Healthcare

Industry

Biotechnology

Employees

952

First IPO Date

February 01, 2001

Key Executives

NameTitlePayYear Born
Mr. John Charles Jacobs M.B.A.President, Chief Executive Officer & Director1.39M1967
Mr. John Joseph Trizzino B.S., M.B.A.President & Chief Operating Officer766,3451960
Mr. James Patrick Kelly C.F.A.Executive Vice President, Chief Financial Officer & Treasurer787,4361966
Ms. Elaine O'HaraExecutive Vice President & Chief Strategy Officer886,1881968
Mr. Troy Morgan Esq., J.D.Senior Vice President, Deputy General Counsel & Chief Compliance Officer01971
Ms. Erika S. TrahanAssociate Director of Investor & Public Relations0N/A
Dr. Henrietta Ukwu FACP FRAPS, M.D.Executive Vice President & Chief Regulatory Officer01967
Ms. Silvia Taylor M.B.A.Executive Vice President and Chief Corporate Affairs & Advocacy Officer0N/A
Mr. Richard P. CrowleyExecutive Vice President & Chief Operating Officer01957
Mr. Ian J. WatkinsExecutive Vice President & Chief Human Resources Officer01963

Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.